Cargando…
Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone
Purpose. 5-Fluorouracil (5-FU) has shown radiosensitizing properties in vitro. This paper reports the effects of radiotherapy and concomitant intravenous 5-FU radiosensitization in the treatment of advanced bone sarcomas. Subjects/methods. Four patients with large inoperable bone sarcomas (three cho...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395373/ https://www.ncbi.nlm.nih.gov/pubmed/18521229 http://dx.doi.org/10.1080/13577149878127 |
_version_ | 1782155491160358912 |
---|---|
author | Zambatis, Charalambos Skarlatos, John Koukourakis, Michael Kosma, Lambrini Giatromanolaki, Alexandra Beroukas, Kostantinos Yannakakis, Dimitrios |
author_facet | Zambatis, Charalambos Skarlatos, John Koukourakis, Michael Kosma, Lambrini Giatromanolaki, Alexandra Beroukas, Kostantinos Yannakakis, Dimitrios |
author_sort | Zambatis, Charalambos |
collection | PubMed |
description | Purpose. 5-Fluorouracil (5-FU) has shown radiosensitizing properties in vitro. This paper reports the effects of radiotherapy and concomitant intravenous 5-FU radiosensitization in the treatment of advanced bone sarcomas. Subjects/methods. Four patients with large inoperable bone sarcomas (three chondrosarcomas and one fibrosarcoma) were treated with hypofractionated radiotherapy and concomitant 5-FU bolus injection (300 mg m(−2)) before each fraction of radiotherapy. A radiation fraction of 5 Gy was given twice a week to a normalized total dose (α/β=4 Gy) of 75 Gy. Results. The regimen was well tolerated, the main toxicity being grade I/II diarrhoea in two cases with pelvic irradiation. Treatment interruption for 1 week was necessary in two cases with pelvic disease but not in two patients treated for sarcoma of the extremities. A complete symptomatic relief was obtained in all cases immediately after the third to the fifth fraction and the median duration was 10 months. Computed tomography scan documented a partial response in 2/4 cases. Discussion. Hypofractionated radiotherapy combined with potential lethal damage inhibitors for bone sarcomas requires further investigation. |
format | Text |
id | pubmed-2395373 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1998 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-23953732008-06-02 Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone Zambatis, Charalambos Skarlatos, John Koukourakis, Michael Kosma, Lambrini Giatromanolaki, Alexandra Beroukas, Kostantinos Yannakakis, Dimitrios Sarcoma Research Article Purpose. 5-Fluorouracil (5-FU) has shown radiosensitizing properties in vitro. This paper reports the effects of radiotherapy and concomitant intravenous 5-FU radiosensitization in the treatment of advanced bone sarcomas. Subjects/methods. Four patients with large inoperable bone sarcomas (three chondrosarcomas and one fibrosarcoma) were treated with hypofractionated radiotherapy and concomitant 5-FU bolus injection (300 mg m(−2)) before each fraction of radiotherapy. A radiation fraction of 5 Gy was given twice a week to a normalized total dose (α/β=4 Gy) of 75 Gy. Results. The regimen was well tolerated, the main toxicity being grade I/II diarrhoea in two cases with pelvic irradiation. Treatment interruption for 1 week was necessary in two cases with pelvic disease but not in two patients treated for sarcoma of the extremities. A complete symptomatic relief was obtained in all cases immediately after the third to the fifth fraction and the median duration was 10 months. Computed tomography scan documented a partial response in 2/4 cases. Discussion. Hypofractionated radiotherapy combined with potential lethal damage inhibitors for bone sarcomas requires further investigation. Hindawi Publishing Corporation 1998-03 /pmc/articles/PMC2395373/ /pubmed/18521229 http://dx.doi.org/10.1080/13577149878127 Text en Copyright © 1998 Hindawi Publishing Corporation. http://creativecommons.org/licenses/by/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Zambatis, Charalambos Skarlatos, John Koukourakis, Michael Kosma, Lambrini Giatromanolaki, Alexandra Beroukas, Kostantinos Yannakakis, Dimitrios Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone |
title | Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone |
title_full | Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone |
title_fullStr | Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone |
title_full_unstemmed | Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone |
title_short | Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone |
title_sort | concurrent hypofractionated radiotherapy and 5-fluorouracil for advanced sarcomas of the bone |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395373/ https://www.ncbi.nlm.nih.gov/pubmed/18521229 http://dx.doi.org/10.1080/13577149878127 |
work_keys_str_mv | AT zambatischaralambos concurrenthypofractionatedradiotherapyand5fluorouracilforadvancedsarcomasofthebone AT skarlatosjohn concurrenthypofractionatedradiotherapyand5fluorouracilforadvancedsarcomasofthebone AT koukourakismichael concurrenthypofractionatedradiotherapyand5fluorouracilforadvancedsarcomasofthebone AT kosmalambrini concurrenthypofractionatedradiotherapyand5fluorouracilforadvancedsarcomasofthebone AT giatromanolakialexandra concurrenthypofractionatedradiotherapyand5fluorouracilforadvancedsarcomasofthebone AT beroukaskostantinos concurrenthypofractionatedradiotherapyand5fluorouracilforadvancedsarcomasofthebone AT yannakakisdimitrios concurrenthypofractionatedradiotherapyand5fluorouracilforadvancedsarcomasofthebone |